10-Q and Current Reports on Form 8-K. All forward-looking statements made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect new information, future events, changed conditions or otherwise after the date of this press release.
Condensed Balance Sheets
December 31, June 30,
2024 2024
-------------- ----------
Cash and cash equivalents $ 14,998,467 $3,094,200
Total assets 15,841,220 4,073,114
Total liabilities 878,799 260,583
Total stockholders' equity 14,962,421 3,812,531
Condensed Statements of Operations
Three months ended December 31,
-----------------------------------
2024 2023
------------------ --------------
Research and development $ 1,220,535 $ 1,062,672
General and administrative 1,367,616 1,697,787
-------------- -------------
Total operating expenses 2,588,151 2,760,459
-------------- -------------
Loss from operations (2,588,151) (2,760,459)
Other (income) expenses:
Interest expense 59,696 31,838
Interest income (7,067) (75,522)
Grant income (177,703) -
Other (47) 594
-------------- -------------
Total other income, net (125,121) (43,090)
-------------- -------------
Net loss $ (2,463,030) $ (2,717,369)
============== =============
Weighted average common shares
outstanding, basic and
diluted 27,415,430 25,789,739
============== =============
Net loss per share, basic and
diluted $ (0.09) $ (0.11)
============== =============
View source version on businesswire.com: https://www.businesswire.com/news/home/20250214598365/en/
CONTACT: Anebulo Pharmaceuticals, Inc.
Daniel George
Chief Financial Officer
(512) 598-0931
Dan@anebulo.com
(END) Dow Jones Newswires
February 14, 2025 16:05 ET (21:05 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。